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Background: There are limited data on the use of the antiepileptic drug (AED) levetiracetam
for the treatment of infants.
Aim: To prospectively evaluate the safety of levetiracetam oral solution and its impact on
epilepsy severity in infants with different seizure types.
Methods: This noninterventional post-authorization safety study included patients 1e11
months of age. Patients' treatment e levetiracetam dose, and addition, withdrawal or
changes in the doses of concomitant medications and AEDs e was at the discretion of the
physician. The primary variable was treatment-emergent adverse events (TEAEs).
Results: Of 101 infants, 75 completed and 26 discontinued the study. Mean age was 6.0
months, 50 were male, most (80%) took 1  concomitant AED and had cryptogenic or
symptomatic epilepsy that was focal (38.6%) or generalized (20.8%), particularly frontal lobe
epilepsy (20.0%) or West syndrome/infantile spasms (20.0%). Among known aetiologies,
congenital factors (22.8%) such as dysplastic lesions or perinatal events (17.8%) were pre-
dominant. Overall, 54.5% of patients had 1 TEAE. Five patients experienced drug-related
TEAEs e convulsion, irritability, somnolence and hypotonia, all listed in the product label,
with the exception of hypotonia, which was reported for one patient and resolved without
any change in study medication. Seven patients discontinued due to TEAEs, mainly due to
infantile spasms and respiratory disorders. At study end, 71.8% of patients showed
improvement in epilepsy severity, 18.8% remained stable and 9.4% showed worsening.
Levetiracetam did not appear to have a negative effect on growth parameters.
Conclusion: In this prospective study, which included the largest number of patients in this
age range so far, levetiracetam was found to be well tolerated and efficacious for the
treatment of infants with epilepsy.
© 2016 UCB Biopharma. Published by Elsevier Ltd on behalf of European Paediatric
Neurology Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Paediatric Neurophysiology Department, University Hospitals of Lyon, Lyon, France. Tel.:
r (A. Arzimanoglou).
by Elsevier Ltd on behalf of European Paediatric Neurology Society. This is an open access
://creativecommons.org/licenses/by-nc-nd/4.0/).
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several important challenges. Childhood epilepsies are a
heterogeneous group of conditions e they differ in their
diagnostic criteria and management and are associated with
markedly different outcomes.1,2 Children present with seizure
types and syndromes not seen in adults, and also frequently
present with comorbid cognitive and behavioural conditions.3
The substantial differences in pharmacokinetics between
adults, children and infantsmust also be considerede age can
affect drug bioavailability, half-life, time to steady state and
elimination.4
Only few well-controlled studies have evaluated the safety
and efficacy of antiepileptic drugs (AEDs) in paediatric pop-
ulations, and children are often excluded from clinical trials of
AEDs before their approval.4e6 Indeed, despite the large
number of AEDs that have become available in recent years,
few have been approved for the treatment of children, espe-
cially those younger than 4 years. In Europe, levetiracetam is
approved as adjunctive therapy for individuals with focal
epilepsy from 1month of age.7 Data on the safety and efficacy
of levetiracetam in children younger than 4 years are available
from a double-blind, randomized, placebo-controlled trial,
which included 12 children aged <12 months, 20 aged 12e24
months and 28 aged 24e48 months.8 In this trial, using 48-h
video electroencephalogram, treatment with levetiracetam
resulted in a greater reduction from baseline in daily seizure
frequency and a greater 50% responder rate compared with
placebo. Levetiracetam appeared to bewell tolerated; only two
adverse events (AEs) e somnolence and irritability e occurred
with a higher incidence in the levetiracetam group than in the
placebo group. Both AEs were transient and were attributed to
the rapid up-titration of levetiracetam. Pharmacokinetic data
are also available for this age group.9 As expected, the overall
elimination half-life of levetiracetam administered as 10%
oral solution was slightly shorter than that reported for chil-
dren aged 6e12 years.9
While several open-label studies of levetiracetam in chil-
dren have included infants,10e12 overall knowledge on the
safety profile of levetiracetam in this patient population re-
mains limited. The objective of this prospective observational
study therefore, was to evaluate the safety of levetiracetam
oral solution and its impact on epilepsy severity in patients
between the ages of 1 and 11 months with different seizure
types in routine clinical practice.2. Methods
This was a non-interventional sentinel sites post-authoriza-
tion safety study (EudraCT number 2009-017333-21) conduct-
ed between January 2011 and November 2013 across 27 sites in
Europe. The study protocol was reviewed by national,
regional, or independent ethics committees, as required by
local regulations for noninterventional studies. Before
participation in the study, the patient's parent(s) or legal rep-
resentative(s) provided informed, written consent.2.1. Patients
One hundred patients aged 1e11 months (inclusive) with a
diagnosis of epilepsy were planned for inclusion in the study;
at least 30 patients were to be aged 1e6 months at the time of
enrolment. Parents/guardians of the children were asked to
enter their child to the study if the physician decided to
initiate therapy with levetiracetam oral solution. Given the
observational nature of the study, patients' treatment plan,
including levetiracetam doses, was at the discretion of the
treating physician, and determined according to standard
practice. Physicians could also add, withdraw, or change
doses of different medications, including concomitant anti-
epileptic drugs (AEDs). Recommended visits were a baseline
visit followed by a maximum of 6 visits, once every 2 months
during the treatment period, to the age of 13 months e if
treatment ended before this, safety data were collected at the
next scheduled visit.2.2. Study outcomes
The primary variable was the incidence of treatment-
emergent adverse events (TEAEs) as reported by parents/
caregivers or observed by the physician. Other safety variables
included observed values at each visit and changes from
baseline in body weight, body length and head circumference.
Raw values of body weight, body length and head circumfer-
ence were converted to z-scores, according to the World
Health Organization growth charts.
The study was not designed to evaluate efficacy per syn-
drome, and there was no primary efficacy variable. However,
as part of routine clinical practice, at each visit the treating
physician evaluated with the patient's parent(s) or guardian,
the types and frequency of seizures experienced by the pa-
tient since Visit 1. With this information, physicians rated
patients' change in epilepsy severity from start to study end
using a 7-point global evaluation scale (GES), with 1 ¼marked
worsening to 7 ¼ marked improvement. The GES is a Likert-
type scale often used in clinical trials; it can be adapted to
provide answers to a variety of clinical and nonclinical ques-
tions. Respondents are asked to indicate their opinion on a
given statement based on a continuum of response categories.
Psychomotor development was also evaluated using a
similar GES during each visit. Physicians were asked to rate
the change in psychomotor development from baseline at the
end of the study (visit 7) with 1 ¼ marked worsening to
7 ¼ marked improvement.
A number of post hoc analyses were also conducted. Six
safety variables, as well as epilepsy severity were analyzed
according to the following subgroups: epilepsy aetiology (un-
known, known); epilepsy aetiology differentiation (genetic,
congenital, perinatal events); epileptic syndrome main cate-
gories (focal, generalized, undetermined, special); epileptic
syndrome further categorization (focal [cryptogenic or symp-
tomatic e frontal, temporal, parietal], generalized [Crypto-
genic or symptomatic e West syndrome]); seizure type
(International League Against Epilepsy seizure classification e
focal, generalized, unclassified); age (<6 months, 6 months);
number of concomitant AEDs at baseline (none, 1, 2) and the
Table 1 e Disease characteristics (safety set).
Epileptic seizure profile/type,a n (%) N ¼ 101
Focal 69 (68.3)
 Simple 25 (24.8)
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 2 0 ( 2 0 1 6 ) 3 6 8e3 7 5370combination of concomitant AEDs at baseline in addition to
levetiracetam (benzodiazepines, phenobarbital, valproate,
vigabatrin).
2.3. Statistical analysis
No formal sample size computations were performed for this
study. However, based on the sample size of 100 patients, the
probability of observing at least one TEAE within a category of
interest (cardiovascular, psychiatric) was 63.4%, assuming an
overall incidence rate of 1.0% for 1 group of TEAEs of interest.
In addition, if zero events within a category of interest are
observed out of 100 subjects, the upper 95% confidence limit
for that event rate is slightly less than 3%. All statistical ana-
lyses were conducted using SAS® version 9.3.
Patient characteristics were based on the enrolled set (ES);
safety and exposure data on the safety set (SS), defined as all
patients in the ES who received at least one dose of study
medication; and efficacy data on the full analysis set (FAS),
defined as all patients in the ES who had at least one post-
baseline efficacy assessment. Complex 43 (42.6)
 Partial evolving to secondary generalized 34 (33.7)
Generalized 41 (40.6)
 Absence 0
 Atypical absence 1 (1.0)
 Myoclonic 8 (7.9)
 Clonic 7 (6.9)
 Tonic 21 (20.8)
 Tonic clonic 17 (16.8)
 Atonic 1 (1.0)
Unclassified 15 (14.9)
Epileptic syndrome, n (%) N ¼ 101
Focal
Idiopathic 4 (4.0)
Cryptogenic or symptomatic 39 (38.6)
 Temporal lobe epilepsy 12 (11.9)
 Frontal lobe epilepsy 20 (19.8)
 Occipital lobe epilepsy 5 (5.0)
 Parietal lobe epilepsy 11 (10.9)
Generalized
Idiopathic 7 (6.9)
 Benign neonatal familial convulsions 2 (2.0)
 Benign neonatal convulsions 1 (1.0)
 Other generalized idiopathic epilepsies not defined
above
4 (4.0)
 Epilepsy with myoclonic-astatic seizures 1 (1.0)
Cryptogenic or symptomatic 21 (20.8)
 West syndrome/infantile spasms 20 (19.8)
 Early infantile epileptic encephalopathy with suppres-
sion burst
1 (1.0)
Symptomatic 8 (7.9)
 Nonspecific aetiology 1 (1.0)
e Other symptomatic generalized epilepsies not
defined above
3 (3.0)
 Specific syndromes
Undetermined whether focal or generalized
Generalized and focal features 9 (8.9)
 Neonatal seizures 6 (5.9)
Other indeterminate epilepsies 15 (14.9)
Special syndromes
Situation-related seizures 6 (5.9)
a Patient could be included in more than one group.3. Results
3.1. Study disposition
Of 101 patients who started, 75 (74.3%) completed the study
and 26 (25.7%) discontinued prematurely. Twelve patients
(11.9%) discontinued due to lack of efficacy, seven (6.9%) due
to AEs, three (3.0%) were lost to follow up, two (2.0%) dis-
continued due to ‘other’ reasons (one patient refused to
swallow and another could not take glucose), one (1.0%)
experienced disease remission, and one (1.0%) discontinued
because the parent/guardian withdrew consent.
3.2. Patient demographics and disease characteristics
In the safety set, the mean age of patients was 6.0 months
(standard deviation [SD] 3 months, range 0e11), with 52 pa-
tients (52.5%) being younger than 6 months. Similar numbers
of males (50, 49.5%) and females (51, 50.5%) were included in
the study; their mean weight was 7.00 kg (SD 1.94, range
3.6e11.0 kg) andmean height was 64.16 cm (SD 8.04 cm, range
46.0e81.0).
The mean age at which patients experienced a first seizure
was 4.153 months (range 0.03e11.34 months) and the mean
duration of epilepsy at study entry was 2.161 months (range
0.03e10.28 months). Most patients had complex focal seizures
(43, 42.6%) and focal evolving to secondary generalized (34,
33.7%) at any time prior to study entry. Simple focal seizures
were reported for 25 patients (24.8%). In terms of syndrome,
most patients had cryptogenic or symptomatic epilepsy that
was focal (39, 38.6%) or generalized (21, 20.8%). Of these syn-
dromes, most were frontal lobe epilepsy or West syndrome/
infantile spasms (20 patients, 19.8% each). The epilepsy
seizure types and syndromes are summarized in Table 1.
Over half the patients (59, 58.4%) had at least one general
concomitant medical condition, the most common being
gastro-oesophageal reflux disease (11 patients, 10.9%),hypotonia (10, 9.9%) and microcephaly (7, 6.9%). Epilepsy
aetiology was unknown in approximately half of patients
(53.5%; Table 2). Among those with a known aetiology, most
had epilepsy attributed to a congenital factor (22.8%) or a
perinatal event (17.8%).
The majority of patients had previously been treated with
at least one AED (60.4%) before entering the study, with the
most frequent being levetiracetam (34.7%), phenobarbital
(30.7%) and vigabatrin (10.9%). Most patients (80.2%) were also
on at least one concomitant AED during the study e the most
frequently used were vigabatrin (33.7%), phenobarbital
(25.7%), valproate sodium (22.8%) and diazepam (19.8%).
Mean studymedication durationwas 152.2± 86.8 days. The
mean daily dose was 316.428 ± 134.767 mg/day (range
98.81e806.03 mg/day) and the mean daily dose per body
Table 2 e Epilepsy aetiology (safety set).
Aetiology,a n (%) N ¼ 101
Unknown 54 (53.5)
Known 47 (46.5)
Genetic 8 (7.9)
Congenital 23 (22.8)
 Cortical dysplasia/dysgenesis 15 (14.9)
 Vascular malformations 2 (2.0)
 Other 9 (8.9)
Perinatal events 18 (17.8)
 Asphyxia during birth 8 (7.9)
 Complication due to pregnancy 2 (2.0)
 Intrauterine viral infection 2 (2.0)
 Other 9 (8.9)
Cranial trauma 1 (1.0)
Cerebral neoplasm 0
Brain surgery 1 (1.0)
Primary degenerative lesion 0
Cerebrovascular accident 3 (3.0)
Cerebral infection 5 (5.0)
Toxic cause 0
Metabolic cause 3 (3.0)
Other 3 (3.0)
a Patient could be included in more than one group.
Table 4 e Treatment-emergent adverse events reported
for at least two patients (safety set).
Preferred term according to MedDRA version 16.1 N ¼ 101
n (%)
Bronchitis 10 (9.9)
Convulsion 10 (9.9)
Pyrexia 8 (7.9)
Diarrhoea 6 (5.9)
Gastroenteritis 4 (4.0)
Irritability 4 (4.0)
Nasopharyngitis 4 (4.0)
Bronchiolitis 3 (3.0)
Ear infection 3 (3.0)
Constipation 3 (3.0)
Vomiting 3 (3.0)
Gastro-oesophageal reflux disease 3 (3.0)
Epilepsy 3 (3.0)
Infantile spasms 3 (3.0)
Hypotonia 2 (2.0)
Lower respiratory tract infection 2 (2.0)
Upper respiratory tract infection 2 (2.0)
Respiratory disorder 2 (2.0)
Respiratory distress 2 (2.0)
Urinary tract infection 2 (2.0)
Viral infection 2 (2.0)
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 2 0 ( 2 0 1 6 ) 3 6 8e3 7 5 371weight was 45.760 ± 15.950 mg/kg/day (range 16.06e87.61 mg/
kg/day).
3.3. Safety outcomes
Overall, 54.5% of patients had at least one TEAE at any time
during the study (Table 3). Five patients (5.0%) had at least one
drug-related TEAE according to the investigatore two patients
(2.0%) experienced irritability and convulsions, one patient
experienced hypotonia (1.0%) and another experienced som-
nolence (1.0%). A summary of the most frequently reported
TEAEs during the study is presented in Table 4.
Twelve patients (11.9%) had at least one severe TEAE, none
of which were considered related to study medication by the
physician. All other TEAEs weremild or moderate in intensity.
Serious AEs were noted in 32 patients (31.7%), of which only
two (both convulsion) were considered drug-related by the
Investigator. Seven patients (6.9%) had at least one TEAE
leading to study discontinuation e these TEAEs were respi-
ratory disorder, respiratory distress and infantile spasms (two
patients each), and irritability, lower respiratory tract infec-
tion, psychomotor retardation and respiratory failure (one
patient each).Table 3 e Overview of treatment-emergent adverse
events (safety set).
AE category N ¼ 101
n (%)
Any TEAEs 55 (54.5)
Serious TEAEs 32 (31.7)
Discontinuation due to TEAEs 7 (6.9)
TEAEs requiring dose change 10 (9.9)
Drug-related TEAEs 5 (5.0)
Severe TEAEs 12 (11.9)
Deaths 6 (5.9)Six deaths were reported during the study. The causes of
death were epilepsy (1 patient), bronchitis and respiratory
distress (1), respiratory distress (1), respiratory disorder (2) and
lower respiratory tract infection and respiratory failure (1).
None of the deaths were related to the study drug, as deter-
mined by the Investigator.
3.4. Changes in body weight, body length and head
circumference
Mean z-scores (SD) at baseline (visit 1) were 0.480 (1.640),
0.586 (2.192) and 0.562 (2.171), respectively for body weight,
body length and head circumference (safety set; Table 5).
Measurements were not available for all patients at all visits;
therefore, baseline values, as well as observed values and
change from baseline for the specific cohort at each visit are
provided (Table 5). Also, given the study design, no patients
attended Visit 6; therefore, no data were attributed to Visit 6.
While baseline and observed values at each visit were nega-
tive, the mean change in z-scores from baseline was positive,
suggesting that these patients exhibited growth.
3.5. Changes in psychomotor development
Data were available from 85 patients at study end (visit 7; FAS)
e relative to baseline, 52.9% of patients showed an improve-
ment, 36.5% of patients remained stable and 10.6% of patients
worsened. On the 7-point scale, 16 patients showed marked
improvement in psychomotor development, while three pa-
tients showed marked worsening (Fig. 1).
3.6. Changes in epilepsy severity
Data were available from 85 patients at visit 7 (FAS) e relative
to baseline, 71.8% showed improvement, 18.8% remained
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showed a marked improvement on the 7-point scale; only
three patients showed marked worsening (Fig. 2).
3.7. Post hoc analyses
Safety and epilepsy outcomes were also evaluated according
to a total of 26 subgroups (see Section 2.2). Overall, no new
safety concerns for levetiracetam oral solution were identified
based on these subgroup analyses. However, the small
numbers of patients in the subgroups preclude any firm con-
clusions. Given that levetiracetam was administered as
adjunctive therapy, only the full results of the post hoc ana-
lyses based on the number of concomitant AEDs at baseline
(none, 1,2) and the combination of concomitant AEDs (those
given at baseline in addition to levetiracetam, including ben-
zodiazepines, phenobarbital, valproate, vigabatrin) are pro-
vided in the online supplement.4. Discussion
In this prospective, noninterventional post-authorization
safety study, 101 infants 1e11 months (inclusive) of age were
treated with levetiracetam oral solution according to routine
clinical practice. Safety analyses revealed no new concerns
and the overall results were consistent with the known safety
profile of levetiracetam. While efficacy was not evaluated
formally, a reduction in the severity of epilepsy based on the
physician's GES was reported for the majority of patients at
study end.
The majority of infants in this study had focal seizures
(68.3%). Complex focal and focal evolving to secondary
generalized seizures were reported for 42.6% and 33.7% of
patients, respectively, while simple focal seizures wereFig. 1 e Change in psychomotor development of patients
from baseline to study end (full analysis set).
Fig. 2 e Change in epilepsy severity from baseline
evaluated at the last visit (full analysis set).
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 2 0 ( 2 0 1 6 ) 3 6 8e3 7 5 373reported for 24.8% of patients. Most infants had cryptogenic or
symptomatic epilepsy that was focal (38.6%) or generalized
(20.8%). In the focal group, most infants had frontal lobe epi-
lepsy (20%), and correspondingly, in the generalized group,
most had West syndrome/infantile spasms (20%). Syndromic
diagnosis in the present study is in agreement with typical
observations in children with severe epilepsies of very early
onset.13,14 Due to ongoing maturation, clinical expression of
seizures is often difficult to characterize with certainty as
focal or generalized, given rapid diffusion of the electrical
discharges.14
The majority of patients (80.2%) were on at least one
concomitant AED during the study, with vigabatrin being the
most frequently used (33.7%). Adjunctive levetiracetam was
well tolerated by the infants in this study e adverse events
reported by the investigators were in line with those already
listed in the product label. Approximately half (54.5%) of pa-
tients had at least one TEAE at any time during the study, with
themost commonbeing bronchitis, pyrexia and persistence of
convulsions. Given that the majority of children in the study
had very severe forms of epilepsy with frequent seizures, the
TEAEs of “convulsion” was not unexpected. Most of the TEAEs
were mild-to-moderate in intensity. Twelve patients (11.9%)
experienced at least one severe TEAE. The most common se-
vere TEAEs were persistence of convulsions and respiratory
disorders, which are frequent at that age range. However,
these were not were considered related to the study medica-
tion by the treating physician. Serious TEAEs were noted in 32
patients e with two exceptions, both convulsions, these were
not considered related to study medication by the physician.
Drug-related TEAEs e convulsion, irritability, hypotonia,
somnolence e were experienced by five patients. With the
exception of hypotonia, all are consistent with the knownsafety profile of levetiracetam and are listed in its product
label. The event of hypotonia was reported for one patiente it
was mild in intensity and resolved uneventfully without any
changes in studymedication. Seven patients discontinued the
study due to TEAEs, which were infantile spasms and respi-
ratory disorders. Six deaths were reported during the study;
no pattern among these deaths was observed and none were
deemed related to the study drug by the investigators.
Infantile spasms are the seizure expression of a severe
epileptic encephalopathy of early childhood, considered to be
one of the most drug-resistant forms of seizures. Conse-
quently, persistence of infantile spasms despite treatment
with levetiracetam could be indicative of lack of efficacy in
this extremely severe form of epilepsy rather than an AE.
Twenty infants with West syndrome (cryptogenic and symp-
tomatic) participated in this study and data from 15 were
available from their last visit. Analysis of results revealed that
none showed worsening in epilepsy severity; on the contrary,
13 showed an improvement in their condition, while in the
other two patients it remained stable. Similarly, the majority
(n ¼ 12) of these patients showed an improvement in psy-
chomotor development; three remained stable and none
showed worsening.
In a retrospective study of 130 patients, which included 12
with infantile spasms, the discontinuation rate of levetir-
acetam was significantly higher in patients with infantile
spasms than in those with Dravet or LennoxeGastaut syn-
dromes.15 However, the patients were older in this study
(mean age at start of levetiracetam adjunctive therapy was 7.7
years) compared with the current study. Furthermore, since
the investigators noted a favourable response among the pa-
tients with infantile spasms, they attributed the discontinu-
ation to the poor tolerability of levetiracetam by these
patients. In another study16 of five patients newly diagnosed
with cryptogenic West syndrome, two became seizure free
following treatment with levetiracetam, two experienced a
50% reduction in seizure frequency, and one had no
improvement in seizure frequency. However, the in-
vestigators did not report the duration of the follow-up and
seizure frequency was based on parental observation. The
study being performed in childrenwith newly diagnosedWest
syndrome, a 50% reduction in the frequency of infantile
spasms cannot be considered as a clinicallymeaningful result.
Positive results for patients with West syndrome treated with
levetiracetam have also been shown in other open-label, un-
controlled studies.10,11
An overall favourable safety and tolerability profile of lev-
etiracetam in children and infants has been reported in
several open-label studies. Notably, in a retrospective study of
28 children younger than 2 years of age with various types of
epilepsy, adverse effects occurred in two patients and were
behavioural in nature.17 Grosso and colleagues included 21
children younger than 4 years of age in one study and 81 in
another.10,11 In both studies, the children had a wide range of
epileptic seizures and syndromes. Investigators noted that
levetiracetam was well tolerated in both studies. In a study
that included 12 children below the age of 4 years and six
below the age of 1 year, very few AEs were reported.12 The
mean daily dose of levetiracetam was 46 mg/kg/day (range
16.0e87.6 mg/kg/day) in this study, which was somewhat
e u r o p e a n j o u r n a l o f p a e d i a t r i c n e u r o l o g y 2 0 ( 2 0 1 6 ) 3 6 8e3 7 5374higher than that used in several other studies. Krief and col-
leagues reported 39 mg/kg/day and Grosso et al. reported
41mg/kg/day (range 25e62mg/kg per day).17,11 Themaximum
recommended dose for infants from 1 month to less than 6
months is 42 mg/kg/day and for infants from 6 months of age
it is 60 mg/kg/day in Europe.7
z-Scores for body weight, body length and head circum-
ference of the infants obtained at baseline were all negative. A
z-score of zero corresponds to the 50th percentile, the refer-
ence mean; therefore, negative values indicate that patients
ranked low on WHO standard growth curves.18,19 Deviations
from normal milestones are reflective of the severity of the
underlying neurological disorders. Very young children with
severe neurological disorders, and seizures as one of the
symptoms, typically present with deviations from standard
bodyweight and height/or head circumference. The change in
z-scores from baseline for body weight and body length were
positive at each visit indicating that the infants grew and
gained weight over time during the study. The change in head
circumference was not as consistent across all visits. Overall,
levetiracetam does not appear to have a negative effect on
growth parameters.
At all visits, most patients had deviations from normal
milestones of psychomotor development. Based on the GES of
psychomotor development, 52.9% of patients showed
improvement, while 36.5% of remained stable and 10.6%
worsened by the end of the study. Physicians also used the
GES to rate change in epilepsy severity. Results indicated that
based on the reports of parents/guardians and physician
observation, epilepsy became less severe in the majority of
patients throughout the study. At study end, 71.8% of patients
showed improvement in their condition, 18.8% remained
stable and 9.4% showed worsening. Of 26 patients who dis-
continued the study, 12 withdrew due to lack or loss of
efficacy.
Given that levetiracetam was administered as adjunctive
therapy in this study, and that the majority (80.2%) were also
on at least one concomitant AED, a post hoc analysis was
conducted to evaluate the safety of levetiracetambased on the
number and specific combination of concomitant AEDs. No
differences emerged in the safety profile of levetiracetam and
AE patterns were similar regardless of the number of
concomitant AEDs and whether levetiracetam was adminis-
tered concomitantly with vigabatrin, phenobarbital, valproate
or diazepam. Furthermore, a pharmacokinetic study of 187
children with epilepsy ranging from 3 to 17 years of age
showed that levetiracetam does not affect the plasma con-
centrations of carbamazepine, valproic acid, topiramate or
lamotrigine.20 Overall, no clear trend or safety concern was
identified when reviewing study outcomes by concomitant
AEDs, or the other subgroups listed in section 2.2. However, as
noted, the strength of conclusions drawn from the post hoc
analyses is limited by the small numbers of patients in the
subgroups.
This was an open-label study, and therefore presents with
the methodological limitations associated with studies that
are not randomized and blinded. However, given the diffi-
culties inherent in conducting randomized controlled trials in
this patient population, results from prospective observa-
tional studies such as the current study can be of value forhealthcare professionals working with infants with epilepsy.
There are few studies evaluating the use of levetiracetam in
infants; to our knowledge, the current study included the
largest number of patients in this age range so far. Since
patients were treated according to local, routine clinical
practice, the results provide an overview of how levetir-
acetam is used for the treatment of infants with different
epileptic seizures and syndromes. Based on the findings of
this study, levetiracetam can be considered an effective and
well-tolerated option for the treatment of infants with
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